Monitor for topline data from OPUS-1 in Q4 2026, which could be a major catalyst. Until then, no new efficacy or safety data to assess; current market cap reflects future potential, not near-term fundamentals.
Price Chart
Executive Summary
Vaxcyte announced completion of enrollment in the OPUS-1 and OPUS-2 Phase 3 trials for its investigational 31-valent pneumococcal vaccine VAX-31. Topline data from OPUS-1 is expected in Q4 2026, with OPUS-2 and OPUS-3 results anticipated in H1 2027. The trials are designed to support a future Biologics License Application (BLA) submission to the FDA, building on prior Breakthrough Therapy designation for VAX-31 in preventing invasive pneumococcal disease and pneumonia.
Key Facts
- Enrollment completed in OPUS-1 (n≈4,000) and OPUS-2 (n≈1,300) Phase 3 trials for VAX-31.
- Topline data from OPUS-1 expected in Q4 2026; OPUS-2 and OPUS-3 results expected in H1 2027.
- OPUS-1 is a pivotal noninferiority trial comparing VAX-31 to Capvaxive® (PCV21) and Prevnar 20® (PCV20) in adults ≥50 years.
- VAX-31 has FDA Breakthrough Therapy Designation for prevention of both IPD and pneumococcal pneumonia in adults.
- No clinical results or financial figures reported — this is a program update on trial enrollment.
Financial Impact
No immediate financial impact; potential long-term value if VAX-31 demonstrates superiority and gains approval.
Risk Factors
- Clinical trial results may not meet endpoints despite favorable Phase 1/2 data.
- Regulatory delays or failure to obtain BLA approval even with positive data.
- High market expectations already priced in given $7.9B market cap despite being pre-revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3260381 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | Insider Cluster | $55.92 $61.58 | ▲ +10.12% | ▲ +10.72% | $56.69 (+1.38%) |
Jul 6, 2026 12w ago | Insider Cluster | $60.67 $53.53 | ▼ −11.77% | ▼ −13.10% | $56.69 (−6.56%) |
Jul 6, 2026 12w ago | Insider Cluster | $60.67 $53.53 | ▼ −11.77% | ▼ −13.10% | $56.69 (−6.56%) |
Jun 26, 2026 13w ago | 144 | $57.72 $54.66 | ▼ −5.30% | ▼ −5.02% | $56.69 (−1.78%) |
Jun 23, 2026 14w ago | 8-K | $53.87 $56.00 | ▲ +3.95% | ▲ +2.02% | $56.69 (+5.23%) |
Jun 19, 2026 15w ago | Insider Cluster | $52.11 $56.20 | ▲ +7.85% | ▲ +8.00% | $56.69 (+8.79%) |
Jun 2, 2026 17w ago | Press Release | $46.93 $58.39 | ▲ +24.42% | ▲ +25.42% | $56.69 (+20.80%) |
May 6, 2026 21w ago | 8-K | $51.48 $46.93 | ▲ +8.84% | ▲ +11.97% | $56.69 (−10.12%) |
Apr 23, 2026 23w ago | DEFA14A | $59.49 $47.39 | ▼ −20.34% | ▼ −24.37% | $56.69 (−4.71%) |
Apr 1, 2026 26w ago | Insider Cluster | $58.50 $57.32 | ▼ −2.02% | ▼ −11.74% | $56.69 (−3.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access